Since 1976, in more than 40 recorded outbreaks to date, Ebola virus disease (EVD) has dramatically affected the human population across the Central African region and adjacent areas. The large West African outbreak (2013–2015) was a game changer in many aspects, not only with regard to geographical location and the number of patients and deaths, but also in terms of the international community’s response it finally triggered; albeit belatedly so. The progress made in our epidemiological and clinical understanding of the disease was immense, as well as advances in the development of an effective vaccine (e.g. rVZV-ZEBOV), specific therapeutic options (e.g. monoclonal antibodies, convalescent whole blood), and candidates for post-exposure prophylaxis (e.g. Favipiravir) [ ]. Read more on Ebola 2018 – Implications for travel health advice and relevance for travel medicine…